TMED T. Rowe Price Health Care ETF
ETF on NASDAQ (US) · Actively managed · Listing
Most notable sale · Abbott Laboratories
Abbott Laboratories sold out
Shares went from 7,720 to 0 ($793K → $0). Was 3.9% of the Mar 31, 2026 portfolio.
Most notable buy · Intuitive Surgical, Inc.
Intuitive Surgical, Inc. raised 11x
Shares went from 134 to 1,410 ($61.8K → $561K). Now 2.4% of the portfolio. Estimated trade $507K.
Largest holding: Eli Lilly and Company, raised 1%, 3,209 shares ($3.85M).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $3.85M · +1% sh | 16.7% |
| UnitedHealth Group Incorporated UNH $1.50M · −26% sh | 6.5% |
| Gilead Sciences, Inc. GILD $1.02M · +34% sh | 4.4% |
| Thermo Fisher Scientific Inc TMO $948K · −<1% sh | 4.1% |
| Danaher Corporation DHR $682K · +23% sh | 3.0% |
| Cencora, Inc. COR $634K · 3.3x sh | 2.8% |
| Agilent Technologies, Inc. A $602K · +51% sh | 2.6% |
| Alnylam Pharmaceuticals, Inc. ALNY $598K · +57% sh | 2.6% |
| Intuitive Surgical, Inc. ISRG $561K · 11x sh | 2.4% |
| Insulet Corporation PODD $548K · 4.5x sh | 2.4% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 98.0% |
| Technology | 1.0% |
| Unclassified | 1.0% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 37.8% |
| Drug Manufacturers - General | 20.6% |
| Medical Instruments & Supplies | 11.2% |
| Medical Devices | 11.0% |
| Healthcare Plans | 10.7% |
| Medical Distribution | 4.2% |
| Medical Care Facilities | 1.5% |
| Other (2) | 2.0% |
| Unclassified | 1.0% |
| Initiations 24 | Value |
|---|---|
| Pfizer, Inc. PFE 1.9% of portfolio | $439K |
| Ascendis Pharma A/S ASND 1.6% of portfolio | $369K |
| McKesson Corporation MCK 1.5% of portfolio | $335K |
| HCA Healthcare, Inc. HCA 1.0% of portfolio | $219K |
| Elevance Health, Inc. ELV 0.8% of portfolio | $176K |
| Tenet Healthcare Corporation THC 0.6% of portfolio | $130K |
| Alignment Healthcare, Inc. ALHC 0.5% of portfolio | $115K |
| Revvity, Inc. RVTY 0.4% of portfolio | $103K |
| Beone Medicines Ltd. ONC 0.4% of portfolio | $91.8K |
| Akeso, Inc. 9926 0.4% of portfolio | $90.1K |
| 4D Molecular Therapeutics, Inc. FDMT 0.3% of portfolio | $73.7K |
| Oruka Therapeutics, Inc. ORKA 0.3% of portfolio | $71.0K |
| Increases 27 | Change |
|---|---|
| Intuitive Surgical, Inc. ISRG $61.8K → $561K | 11x |
| Cencora, Inc. COR $215K → $634K | 3.3x |
| Insulet Corporation PODD $169K → $548K | 4.5x |
| Gilead Sciences, Inc. GILD $839K → $1.02M | +34% |
| Alnylam Pharmaceuticals, Inc. ALNY $418K → $598K | +57% |
| Agilent Technologies, Inc. A $341K → $602K | +51% |
| Denali Therapeutics Inc. DNLI $98.2K → $282K | 2.1x |
| IDEXX Laboratories, Inc. IDXX $149K → $271K | +94% |
| BioNTech SE BNTX $163K → $297K | +74% |
| Danaher Corporation DHR $553K → $682K | +23% |
| Stryker Corporation SYK $406K → $511K | +31% |
| DexCom, Inc. DXCM $204K → $335K | +53% |
| Reductions 44 | Change |
|---|---|
| UnitedHealth Group Incorporated UNH $1.33M → $1.50M | −26% |
| Humana Inc. HUM $318K → $286K | −61% |
| Becton, Dickinson and Company BDX $346K → $166K | −50% |
| Adaptive Biotechnologies Corporation ADPT $168K → $96.1K | −63% |
| Molina Healthcare Inc MOH $144K → $95.1K | −62% |
| Rapport Therapeutics, Inc. RAPP $106K → $47.0K | −67% |
| Erasca, Inc. ERAS $103K → $26.7K | −77% |
| Xenon Pharmaceuticals Inc. XENE $149K → $73.4K | −52% |
| Kymera Therapeutics, Inc. KYMR $125K → $109K | −37% |
| Waters Corporation WAT $355K → $388K | −13% |
| NovoCure Limited NVCR $93.7K → $72.2K | −45% |
| Amylyx Pharmaceuticals, Inc. AMLX $79.4K → $46.9K | −54% |
| Terminations 30 | Change |
|---|---|
| Abbott Laboratories ABT was $793K | −100% |
| Medtronic plc. MDT was $454K | −100% |
| Boston Scientific Corporation BSX was $298K | −100% |
| ASCENDIS PHARMA A/S - ADR was $282K | −100% |
| APELLIS PHARMACEUTICALS INC was $208K | −100% |
| Regeneron Pharmaceuticals, Inc. REGN was $206K | −100% |
| Bristol-Myers Squibb Company BMY was $148K | −100% |
| Agios Pharmaceuticals, Inc. AGIO was $132K | −100% |
| Novo Nordisk A/S NVO was $118K | −100% |
| Align Technology, Inc. ALGN was $109K | −100% |
| Alkermes plc ALKS was $108K | −100% |
| Natera, Inc. NTRA was $101K | −100% |
The other 12 initiations
OnKure Therapeutics, Inc. ($69.9K), Sartorius Aktiengesellschaft ($68.7K), Kardigan, Inc. ($64.3K), Maze Therapeutics, Inc. ($49.4K), Allogene Therapeutics, Inc. ($48.2K), Oric Pharmaceuticals, Inc. ($47.4K), Spyre Therapeutics, Inc. ($46.6K), Damora Therapeutics Inc ($46.5K), Avalyn Pharma Inc. ($41.0K), Abivax SA ($27.9K), CENTESSA PHARMACEUTICALS-ADR CVR ($0), CONTRA APELLIS PHARMAC COMMON STOCK ($0)
The other 15 increases
Elanco Animal Health Incorporated (+33%), Immunome, Inc. (+41%), Biogen Inc. (+19%), Immatics N.V. (+20%), Vaxcyte, Inc. (+13%), Eli Lilly and Company (+1%), GeneDx Holdings Corp. (+35%), PROCEPT BioRobotics Corporation (+35%), Repligen Corporation (+5%), Schrodinger, Inc. (+35%), Shattuck Labs, Inc. (+5%), Cabaletta Bio, Inc. (+5%), Caris Life Sciences, Inc. (+9%), Dyne Therapeutics, Inc. (+<1%), CVS Health Corporation (+1%)
The other 32 reductions
West Pharmaceutical Services, Inc. (−12%), Avalo Therapeutics, Inc. (−38%), Stevanato Group S.p.A. (−41%), Biohaven Ltd. (−68%), Apogee Therapeutics, Inc. (−21%), Prime Medicine, Inc. (−67%), Annexon, Inc. (−78%), Aktis Oncology, Inc. (−44%), MoonLake Immunotherapeutics (−20%), GRAIL, Inc. (−38%), Ionis Pharmaceuticals, Inc. (−40%), Kodiak Sciences Inc (−21%), Karyopharm Therapeutics Inc. (−45%), CRISPR Therapeutics AG (−46%), Disc Medicine, Inc. (−29%), Cytokinetics, Incorporated (−3%), Sarepta Therapeutics, Inc. (−11%), Enliven Therapeutics, Inc. (−21%), Stoke Therapeutics, Inc. (−12%), The Cooper Companies, Inc. (−5%) and 12 more
The other 18 terminations
Guardant Health, Inc. ($85.8K), CENTESSA PHARMACEUTICALS-ADR ($79.0K), Edwards Lifesciences Corporation ($77.8K), Immunocore Holdings plc ($74.4K), ICON plc ($67.7K), Travere Therapeutics, Inc. ($58.9K), Relay Therapeutics, Inc. ($51.8K), YPSOMED HOLDING AG-REG ($49.8K), Oscar Health, Inc. ($45.9K), Charles River Laboratories International, Inc. ($43.5K), Bruker Corporation ($43.2K), Bio-Techne Corp ($31.0K), Olema Oncology, Inc. ($29.8K), SOLENO THERAPEUTICS INC ($26.1K), Janux Therapeutics, Inc. ($20.2K), Tango Therapeutics, Inc. ($19.5K), BillionToOne, Inc. ($18.0K), Revolution Medicines, Inc. ($9.24K)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Feb 26, 2026.
The fund seeks long-term capital appreciation.
Principal investment strategies
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The fund defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund references the MSCI GICS (Global Industry Classification Standard) Health Care sector to identify such companies. Any derivatives that provide exposure to the investment focus suggested by the fund's name, or to one or more market risk factors associated with the investment focus suggested by the fund's name, are counted (as applicable) toward compliance with the fund's 80% investment policy. T. ROWE PRICE 2 As a fundamental policy, the fund will concentrate (invest more than 25% of its net assets) in health care companies. The majority of the fund will be invested in equity securities, such as common stocks. While most assets are typically invested in U.S. common stocks, the fund may invest in foreign stocks in keeping with its objective. The fund uses fundamental, bottom-up analysis and may invest in companies of any market capitalization. The adviser may use both growth and value approaches in selecting investments for the fund. The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.
Management and Contact
- Adviser
- T. Rowe Price Associates, Inc.
- Sub-adviser
- T. Rowe Price Investment Management, Inc.
- Portfolio managers
-
Sal Rais (Portfolio Manager and Chair of Investment Advisory Committee, since 2025, 2021)
- Phone
- 1-800-638-5660
- [email protected]
Holdings as of Jun 30, 2026
The full portfolio as of the quarter end Jun 30, 2026, from the fund's report to the SEC (Form N-PORT, filed Aug 27, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of Mar 31, 2026.
102 lines, 93 linked, weights sum to 100.00% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| ELI LILLY & CO | US5324571083 | Equity | 3,209 | +20 | 16.71% | $ 3.849M |
| UNITEDHEALTH GROUP INC | US91324P1021 | Equity | 3,614 | −1,284 | 6.52% | $ 1.502M |
| GILEAD SCIENCES INC | US3755581036 | Equity | 8,084 | +2,064 | 4.44% | $ 1.021M |
| THERMO FISHER SCIENTIFIC INC | US8835561023 | Equity | 1,890 | −3 | 4.11% | $ 947.57K |
| DANAHER CORP | US2358511028 | Equity | 3,580 | +662 | 2.96% | $ 681.918K |
| CENCORA INC | US03073E1055 | Equity | 2,240 | +1,555 | 2.75% | $ 633.875K |
| AGILENT TECHNOLOGIES INC | US00846U1016 | Equity | 4,530 | +1,534 | 2.61% | $ 601.72K |
| ALNYLAM PHARMACEUTICALS INC | US02043Q1076 | Equity | 1,986 | +724 | 2.60% | $ 597.846K |
| INTUITIVE SURGICAL INC | US46120E6023 | Equity | 1,410 | +1,276 | 2.43% | $ 560.729K |
| INSULET CORP | US45784P1012 | Equity | 3,601 | +2,798 | 2.38% | $ 548.252K |
| STRYKER CORP | US8636671013 | Equity | 1,624 | +389 | 2.22% | $ 511.3K |
| DYNE THERAPEUTICS INC | US26818M1080 | Equity | 21,069 | +100 | 2.03% | $ 467.942K |
| ELANCO ANIMAL HEALTH INC | US28414H1032 | Equity | 17,864 | +4,436 | 1.91% | $ 439.633K |
| PFIZER INC | US7170811035 | Equity | 18,228 | new +18,228 | 1.91% | $ 438.93K |
| CYTOKINETICS INC | US23282W6057 | Equity | 4,564 | −158 | 1.69% | $ 388.807K |
| WATERS CORP | US9418481035 | Equity | 1,034 | −158 | 1.68% | $ 387.791K |
| WEST PHARMACEUTICAL SERVICES | US9553061055 | Equity | 1,060 | −138 | 1.65% | $ 380.54K |
| ASCENDIS PHARMA A/S | DK0060615755 | Equity | 1,382 | new +1,382 | 1.60% | $ 368.607K |
| BIOGEN INC | US09062X1037 | Equity | 1,654 | +264 | 1.55% | $ 357.363K |
| MCKESSON CORP | US58155Q1031 | Equity | 444 | new +444 | 1.46% | $ 335.486K |
| DEXCOM INC | US2521311074 | Equity | 4,976 | +1,725 | 1.46% | $ 335.134K |
| IMMUNOME INC | US45257U1088 | Equity | 15,009 | +4,340 | 1.38% | $ 318.041K |
| BIONTECH SE-ADR | US09075V1026 | Equity | 3,188 | +1,359 | 1.29% | $ 296.643K |
| HUMANA INC | US4448591028 | Equity | 721 | −1,114 | 1.24% | $ 286.396K |
| DENALI THERAPEUTICS INC | US24823R1059 | Equity | 10,962 | +5,846 | 1.22% | $ 281.943K |
| CVS HEALTH CORP | US1266501006 | Equity | 2,717 | +19 | 1.22% | $ 281.074K |
| IDEXX LABORATORIES INC | US45168D1046 | Equity | 515 | +249 | 1.18% | $ 271.117K |
| VAXCYTE INC | US92243G1085 | Equity | 4,655 | +519 | 1.18% | $ 270.595K |
| METTLER-TOLEDO INTERNATIONAL | US5926881054 | Equity | 174 | −4 | 0.97% | $ 222.287K |
| HCA HEALTHCARE INC | US40412C1018 | Equity | 562 | new +562 | 0.95% | $ 219.118K |
| IMMATICS NV | NL0015285941 | Equity | 19,722 | +3,354 | 0.87% | $ 199.784K |
| REPLIGEN CORP | US7599161095 | Equity | 1,430 | +71 | 0.85% | $ 195.109K |
| ELEVANCE HEALTH INC | US0367521038 | Equity | 456 | new +456 | 0.77% | $ 176.349K |
| SHATTUCK LABS INC | US82024L1035 | Equity | 25,348 | +1,237 | 0.76% | $ 175.915K |
| APOGEE THERAPEUTICS INC | US03770N1019 | Equity | 1,309 | −349 | 0.75% | $ 173.744K |
|
STATE STREET INS US GO MM FD-IS
|
US8574927062 | Money market | 169,172.27 | +142,163.98 | 0.73% | $ 169.172K |
| BECTON DICKINSON AND CO | US0758871091 | Equity | 1,098 | −1,104 | 0.72% | $ 166.16K |
| MOONLAKE IMMUNOTHERAPEUTICS | KY61559X1045 | Equity | 7,823 | −1,896 | 0.66% | $ 152.314K |
| COOPER COS INC/THE | US2166485019 | Equity | 2,088 | −109 | 0.65% | $ 149.73K |
| CABALETTA BIO INC | US12674W1099 | Equity | 45,659 | +2,029 | 0.62% | $ 141.999K |
| CG ONCOLOGY INC | US1569441009 | Equity | 1,996 | −32 | 0.62% | $ 141.816K |
| TENET HEALTHCARE CORP | US88033G4073 | Equity | 693 | new +693 | 0.56% | $ 129.646K |
| BICARA THERAPEUTICS INC | US0554771032 | Equity | 4,103 | −4,207 | 0.53% | $ 121.818K |
| ALIGNMENT HEALTHCARE INC | US01625V1044 | Equity | 4,840 | new +4,840 | 0.50% | $ 115.24K |
| SAREPTA THERAPEUTICS INC | US8036071004 | Equity | 6,068 | −749 | 0.47% | $ 109.042K |
| KYMERA THERAPEUTICS INC | US5015751044 | Equity | 949 | −548 | 0.47% | $ 108.822K |
| REVVITY INC | US7140461093 | Equity | 926 | new +926 | 0.45% | $ 103.027K |
| ADAPTIVE BIOTECHNOLOGIES | US00650F1093 | Equity | 4,479 | −7,605 | 0.42% | $ 96.075K |
| MOLINA HEALTHCARE INC | US60855R1005 | Equity | 416 | −666 | 0.41% | $ 95.139K |
| BEONE MEDICINES LTD-ADR | US07725L1026 | Equity | 322 | new +322 | 0.40% | $ 91.76K |
| MAPLIGHT THERAPEUTICS INC | US56565P1030 | Equity | 2,543 | −2,567 | 0.40% | $ 91.141K |
| AKESO INC | KYG0146B1032 | Equity | 8,000 | new +8,000 | 0.39% | $ 90.078K |
| KODIAK SCIENCES INC | US50015M1099 | Equity | 2,147 | −558 | 0.36% | $ 83.647K |
| GENEDX HOLDINGS CORP | US81663L2007 | Equity | 1,200 | +309 | 0.36% | $ 82.38K |
| DIANTHUS THERAPEUTICS INC | US2528281080 | Equity | 816 | −32 | 0.35% | $ 79.544K |
| AVALO THERAPEUTICS INC | US05338F3064 | Equity | 4,287 | −2,627 | 0.34% | $ 79.224K |
| INCYTE CORP | US45337C1027 | Equity | 669 | −729 | 0.33% | $ 75.838K |
| 4D MOLECULAR THERAPEUTICS IN | US35104E1001 | Equity | 5,545 | new +5,545 | 0.32% | $ 73.749K |
| XENON PHARMACEUTICALS INC | CA98420N1050 | Equity | 1,216 | −1,342 | 0.32% | $ 73.398K |
| NOVOCURE LTD | JE00BYSS4X48 | Equity | 4,764 | −3,834 | 0.31% | $ 72.175K |
| EIKON THERAPEUTICS INC | US2825641036 | Equity | 5,522 | −318 | 0.31% | $ 72.062K |
| ORUKA THERAPEUTICS INC | US6876041087 | Equity | 746 | new +746 | 0.31% | $ 70.997K |
| STOKE THERAPEUTICS INC | US86150R1077 | Equity | 2,167 | −301 | 0.31% | $ 70.904K |
| ONKURE THERAPEUTICS INC | US68277Q1058 | Equity | 15,335 | new +15,335 | 0.30% | $ 69.928K |
| STEVANATO GROUP SPA | IT0005452658 | Equity | 3,869 | −2,640 | 0.30% | $ 69.913K |
| SARTORIUS AG | DE0007165607 | Equity | 320 | new +320 | 0.30% | $ 68.734K |
| CARIS LIFE SCIENCES INC | US1421521071 | Equity | 3,694 | +317 | 0.29% | $ 65.827K |
| KARDIGAN INC | US4859251013 | Equity | 2,695 | new +2,695 | 0.28% | $ 64.276K |
| CRINETICS PHARMACEUTICALS IN | US22663K1079 | Equity | 1,596 | −162 | 0.26% | $ 59.722K |
| GRAIL INC | US3847471014 | Equity | 868 | −536 | 0.26% | $ 59.258K |
| ARCUS BIOSCIENCES INC | US03969F1093 | Equity | 1,868 | −1,965 | 0.25% | $ 57.59K |
| MAZE THERAPEUTICS INC | US5787841007 | Equity | 1,656 | new +1,656 | 0.21% | $ 49.415K |
| AKTIS ONCOLOGY INC | US01021M1045 | Equity | 1,517 | −1,204 | 0.21% | $ 48.893K |
| ALLOGENE THERAPEUTICS INC | US0197701065 | Equity | 23,151 | new +23,151 | 0.21% | $ 48.154K |
| ORIC PHARMACEUTICALS INC | US68622P1093 | Equity | 4,380 | new +4,380 | 0.21% | $ 47.435K |
| RAPPORT THERAPEUTICS INC | US75383L1026 | Equity | 1,127 | −2,265 | 0.20% | $ 46.962K |
| AMYLYX PHARMACEUTICALS INC | US03237H1014 | Equity | 2,611 | −3,100 | 0.20% | $ 46.894K |
| Spyre Therapeutics Inc | US00773J2024 | Equity | 525 | new +525 | 0.20% | $ 46.61K |
|
Damora Therapeutics Inc
|
US36322Q2066 | Equity | 1,788 | new +1,788 | 0.20% | $ 46.506K |
| ENLIVEN THERAPEUTICS INC | US29337E1029 | Equity | 891 | −244 | 0.20% | $ 45.218K |
| PROCEPT BIOROBOTICS CORP | US74276L1052 | Equity | 1,951 | +501 | 0.19% | $ 44.054K |
| DISC MEDICINE INC | US2546041011 | Equity | 600 | −241 | 0.19% | $ 43.884K |
| AVALYN PHARMA INC | US05348Y1055 | Equity | 1,244 | new +1,244 | 0.18% | $ 40.952K |
| IONIS PHARMACEUTICALS INC | US4622221004 | Equity | 509 | −341 | 0.18% | $ 40.359K |
| SCHRODINGER INC | US80810D1037 | Equity | 2,236 | +574 | 0.16% | $ 36.335K |
| BLACK DIAMOND THERAPEUTICS I | US09203E1055 | Equity | 15,259 | −284 | 0.12% | $ 28.229K |
| ABIVAX SA-ADR | US00370M1036 | Equity | 209 | new +209 | 0.12% | $ 27.851K |
| ERASCA INC | US29479A1088 | Equity | 1,460 | −4,888 | 0.12% | $ 26.747K |
| PERSONALIS INC | US71535D1063 | Equity | 1,990 | −1,990 | 0.12% | $ 26.666K |
| KARYOPHARM THERAPEUTICS INC | US48576U2050 | Equity | 2,470 | −2,014 | 0.10% | $ 24.132K |
| PRIME MEDICINE INC | US74168J1016 | Equity | 6,152 | −12,299 | 0.10% | $ 22.701K |
| IMMUNOVANT INC | US45258J1025 | Equity | 580 | −168 | 0.10% | $ 22.347K |
| BIOHAVEN LTD | VGG1110E1079 | Equity | 1,458 | −3,165 | 0.09% | $ 21.695K |
| CRISPR THERAPEUTICS AG | CH0334081137 | Equity | 381 | −328 | 0.09% | $ 20.78K |
|
KARYOPHARM WTS 10.28 TC4ZZLSW8
|
Equity | 3,159 | 0 | 0.08% | $ 17.514K | |
| ANNEXON INC | US03589W1027 | Equity | 2,087 | −7,228 | 0.05% | $ 11.917K |
|
JASPER THERA WTS 3/30 TC8U3IZJ8
|
Equity | 5,370 | 0 | 0.01% | $ 1,524.01 | |
|
CONTRA 89BIO INC COMMON STOCK
|
US282CVR0187 | Equity | 2,477 | 0 | 0.00% | $ 0.00 |
|
CENTESSA PHARMACEUTICALS-ADR CVR
|
152CVR015 | Equity | 1,490 | new +1,490 | 0.00% | $ 0.00 |
|
CONTRA APELLIS PHARMAC COMMON STOCK
|
US037CVR0169 | Equity | 499 | new +499 | 0.00% | $ 0.00 |
|
APPLIED THERAPEUTICS INC CVR
|
APLT 038CVR031 | Equity | 153,622 | 0 | 0.00% | $ 0.00 |
|
METSERA INC CVR
|
MTSR 592CVR013 | Equity | 1,892 | 0 | 0.00% | $ 0.00 |
Trades Mar 31, 2026 to Jun 30, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| ABBOTT LABORATORIES | Closed | 7,720 | — | −7,720 | $ -792.612K | |
| UNITEDHEALTH GROUP INC | Sold | 4,898 | 3,614 | −1,284 | $ -533.669K | |
| INTUITIVE SURGICAL INC | Bought | 134 | 1,410 | +1,276 | $ 507.44K | |
| MEDTRONIC PLC | Closed | 5,245 | — | −5,245 | $ -454.479K | |
| HUMANA INC | Sold | 1,835 | 721 | −1,114 | $ -442.503K | |
| CENCORA INC | Bought | 685 | 2,240 | +1,555 | $ 440.034K | |
| PFIZER INC | New | — | 18,228 | +18,228 | $ 438.93K | |
| INSULET CORP | Bought | 803 | 3,601 | +2,798 | $ 425.996K | |
| ASCENDIS PHARMA A/S | New | — | 1,382 | +1,382 | $ 368.607K | |
| MCKESSON CORP | New | — | 444 | +444 | $ 335.486K | |
| BOSTON SCIENTIFIC CORP | Closed | 4,745 | — | −4,745 | $ -297.749K | |
|
ASCENDIS PHARMA A/S - ADR
|
Closed | 1,235 | — | −1,235 | $ -282.482K | |
| GILEAD SCIENCES INC | Bought | 6,020 | 8,084 | +2,064 | $ 260.766K | |
| HCA HEALTHCARE INC | New | — | 562 | +562 | $ 219.118K | |
| ALNYLAM PHARMACEUTICALS INC | Bought | 1,262 | 1,986 | +724 | $ 217.946K | |
|
APELLIS PHARMACEUTICALS INC
|
Closed | 5,162 | — | −5,162 | $ -207.667K | |
| REGENERON PHARMACEUTICALS | Closed | 267 | — | −267 | $ -206.295K | |
| AGILENT TECHNOLOGIES INC | Bought | 2,996 | 4,530 | +1,534 | $ 203.761K | |
| ELEVANCE HEALTH INC | New | — | 456 | +456 | $ 176.349K | |
| BECTON DICKINSON AND CO | Sold | 2,202 | 1,098 | −1,104 | $ -167.068K | |
| ADAPTIVE BIOTECHNOLOGIES | Sold | 12,084 | 4,479 | −7,605 | $ -163.127K | |
| MOLINA HEALTHCARE INC | Sold | 1,082 | 416 | −666 | $ -152.314K | |
| DENALI THERAPEUTICS INC | Bought | 5,116 | 10,962 | +5,846 | $ 150.359K | |
| BRISTOL-MYERS SQUIBB CO | Closed | 2,432 | — | −2,432 | $ -147.501K | |
| AGIOS PHARMACEUTICALS INC | Closed | 3,906 | — | −3,906 | $ -132.14K | |
| IDEXX LABORATORIES INC | Bought | 266 | 515 | +249 | $ 131.084K | |
| TENET HEALTHCARE CORP | New | — | 693 | +693 | $ 129.646K | |
| BIONTECH SE-ADR | Bought | 1,829 | 3,188 | +1,359 | $ 126.455K | |
| DANAHER CORP | Bought | 2,918 | 3,580 | +662 | $ 126.098K | |
| BICARA THERAPEUTICS INC | Sold | 8,310 | 4,103 | −4,207 | $ -124.906K | |
| STRYKER CORP | Bought | 1,235 | 1,624 | +389 | $ 122.473K | |
| NOVO-NORDISK A/S-SPONS ADR | Closed | 3,200 | — | −3,200 | $ -117.6K | |
| DEXCOM INC | Bought | 3,251 | 4,976 | +1,725 | $ 116.179K | |
| ALIGNMENT HEALTHCARE INC | New | — | 4,840 | +4,840 | $ 115.24K | |
| ELANCO ANIMAL HEALTH INC | Bought | 13,428 | 17,864 | +4,436 | $ 109.17K | |
| ALIGN TECHNOLOGY INC | Closed | 634 | — | −634 | $ -108.687K | |
| ALKERMES PLC | Closed | 3,048 | — | −3,048 | $ -107.777K | |
| REVVITY INC | New | — | 926 | +926 | $ 103.027K | |
| NATERA INC | Closed | 504 | — | −504 | $ -100.795K | |
| RAPPORT THERAPEUTICS INC | Sold | 3,392 | 1,127 | −2,265 | $ -94.383K | |
| MAPLIGHT THERAPEUTICS INC | Sold | 5,110 | 2,543 | −2,567 | $ -92.001K | |
| IMMUNOME INC | Bought | 10,669 | 15,009 | +4,340 | $ 91.965K | |
| BEONE MEDICINES LTD-ADR | New | — | 322 | +322 | $ 91.76K | |
| AKESO INC | New | — | 8,000 | +8,000 | $ 90.078K | |
| ERASCA INC | Sold | 6,348 | 1,460 | −4,888 | $ -89.548K | |
| GUARDANT HEALTH INC | Closed | 929 | — | −929 | $ -85.812K | |
| INCYTE CORP | Sold | 1,398 | 669 | −729 | $ -82.639K | |
| XENON PHARMACEUTICALS INC | Sold | 2,558 | 1,216 | −1,342 | $ -81.003K | |
|
CENTESSA PHARMACEUTICALS-ADR
|
Closed | 1,990 | — | −1,990 | $ -79.043K | |
| EDWARDS LIFESCIENCES CORP | Closed | 971 | — | −971 | $ -77.758K | |
| IMMUNOCORE HOLDINGS PLC-ADR | Closed | 2,468 | — | −2,468 | $ -74.41K | |
| 4D MOLECULAR THERAPEUTICS IN | New | — | 5,545 | +5,545 | $ 73.749K | |
| ORUKA THERAPEUTICS INC | New | — | 746 | +746 | $ 70.997K | |
| ONKURE THERAPEUTICS INC | New | — | 15,335 | +15,335 | $ 69.928K | |
| SARTORIUS AG | New | — | 320 | +320 | $ 68.734K | |
| ICON PLC | Closed | 612 | — | −612 | $ -67.724K | |
| KARDIGAN INC | New | — | 2,695 | +2,695 | $ 64.276K | |
| KYMERA THERAPEUTICS INC | Sold | 1,497 | 949 | −548 | $ -62.839K | |
| ARCUS BIOSCIENCES INC | Sold | 3,833 | 1,868 | −1,965 | $ -60.581K | |
| WATERS CORP | Sold | 1,192 | 1,034 | −158 | $ -59.256K | |
| TRAVERE THERAPEUTICS INC | Closed | 1,982 | — | −1,982 | $ -58.885K | |
| NOVOCURE LTD | Sold | 8,598 | 4,764 | −3,834 | $ -58.085K | |
| BIOGEN INC | Bought | 1,390 | 1,654 | +264 | $ 57.04K | |
| AMYLYX PHARMACEUTICALS INC | Sold | 5,711 | 2,611 | −3,100 | $ -55.676K | |
| RELAY THERAPEUTICS INC | Closed | 5,205 | — | −5,205 | $ -51.79K | |
|
YPSOMED HOLDING AG-REG
|
Closed | 142 | — | −142 | $ -49.78K | |
| WEST PHARMACEUTICAL SERVICES | Sold | 1,198 | 1,060 | −138 | $ -49.542K | |
| MAZE THERAPEUTICS INC | New | — | 1,656 | +1,656 | $ 49.415K | |
| AVALO THERAPEUTICS INC | Sold | 6,914 | 4,287 | −2,627 | $ -48.547K | |
| ALLOGENE THERAPEUTICS INC | New | — | 23,151 | +23,151 | $ 48.154K | |
| STEVANATO GROUP SPA | Sold | 6,509 | 3,869 | −2,640 | $ -47.705K | |
| ORIC PHARMACEUTICALS INC | New | — | 4,380 | +4,380 | $ 47.435K | |
| BIOHAVEN LTD | Sold | 4,623 | 1,458 | −3,165 | $ -47.095K | |
| Spyre Therapeutics Inc | New | — | 525 | +525 | $ 46.61K | |
|
Damora Therapeutics Inc
|
New | — | 1,788 | +1,788 | $ 46.506K | |
| APOGEE THERAPEUTICS INC | Sold | 1,658 | 1,309 | −349 | $ -46.323K | |
| OSCAR HEALTH INC - CLASS A | Closed | 3,999 | — | −3,999 | $ -45.869K | |
| PRIME MEDICINE INC | Sold | 18,451 | 6,152 | −12,299 | $ -45.383K | |
| CHARLES RIVER LABORATORIES | Closed | 252 | — | −252 | $ -43.47K | |
| BRUKER CORP | Closed | 1,196 | — | −1,196 | $ -43.2K | |
| ANNEXON INC | Sold | 9,315 | 2,087 | −7,228 | $ -41.272K | |
| AVALYN PHARMA INC | New | — | 1,244 | +1,244 | $ 40.952K | |
| AKTIS ONCOLOGY INC | Sold | 2,721 | 1,517 | −1,204 | $ -38.805K | |
| MOONLAKE IMMUNOTHERAPEUTICS | Sold | 9,719 | 7,823 | −1,896 | $ -36.915K | |
| GRAIL INC | Sold | 1,404 | 868 | −536 | $ -36.593K | |
| IMMATICS NV | Bought | 16,368 | 19,722 | +3,354 | $ 33.976K | |
| BIO-TECHNE CORP | Closed | 593 | — | −593 | $ -30.99K | |
| VAXCYTE INC | Bought | 4,136 | 4,655 | +519 | $ 30.169K | |
| OLEMA PHARMACEUTICALS INC | Closed | 1,997 | — | −1,997 | $ -29.775K | |
| ABIVAX SA-ADR | New | — | 209 | +209 | $ 27.851K | |
| IONIS PHARMACEUTICALS INC | Sold | 850 | 509 | −341 | $ -27.038K | |
| PERSONALIS INC | Sold | 3,980 | 1,990 | −1,990 | $ -26.666K | |
|
SOLENO THERAPEUTICS INC
|
Closed | 780 | — | −780 | $ -26.114K | |
| ELI LILLY & CO | Bought | 3,189 | 3,209 | +20 | $ 23.989K | |
| KODIAK SCIENCES INC | Sold | 2,705 | 2,147 | −558 | $ -21.74K | |
| GENEDX HOLDINGS CORP | Bought | 891 | 1,200 | +309 | $ 21.213K | |
| JANUX THERAPEUTICS INC | Closed | 1,455 | — | −1,455 | $ -20.225K | |
| KARYOPHARM THERAPEUTICS INC | Sold | 4,484 | 2,470 | −2,014 | $ -19.677K | |
| TANGO THERAPEUTICS INC | Closed | 933 | — | −933 | $ -19.518K | |
| BILLIONTOONE INC CL A | Closed | 228 | — | −228 | $ -17.998K | |
| CRISPR THERAPEUTICS AG | Sold | 709 | 381 | −328 | $ -17.889K | |
| DISC MEDICINE INC | Sold | 841 | 600 | −241 | $ -17.627K | |
| CYTOKINETICS INC | Sold | 4,722 | 4,564 | −158 | $ -13.46K | |
| SAREPTA THERAPEUTICS INC | Sold | 6,817 | 6,068 | −749 | $ -13.46K | |
| ENLIVEN THERAPEUTICS INC | Sold | 1,135 | 891 | −244 | $ -12.383K | |
| PROCEPT BIOROBOTICS CORP | Bought | 1,450 | 1,951 | +501 | $ 11.313K | |
| STOKE THERAPEUTICS INC | Sold | 2,468 | 2,167 | −301 | $ -9,848.72 | |
| REPLIGEN CORP | Bought | 1,359 | 1,430 | +71 | $ 9,687.24 | |
| SCHRODINGER INC | Bought | 1,662 | 2,236 | +574 | $ 9,327.50 | |
| REVOLUTION MEDICINES INC | Closed | 95 | — | −95 | $ -9,238.75 | |
| SHATTUCK LABS INC | Bought | 24,111 | 25,348 | +1,237 | $ 8,584.78 | |
| COOPER COS INC/THE | Sold | 2,197 | 2,088 | −109 | $ -7,816.39 | |
| IMMUNOVANT INC | Sold | 748 | 580 | −168 | $ -6,473.04 | |
| CABALETTA BIO INC | Bought | 43,630 | 45,659 | +2,029 | $ 6,310.19 | |
| CRINETICS PHARMACEUTICALS IN | Sold | 1,758 | 1,596 | −162 | $ -6,062.04 | |
| CARIS LIFE SCIENCES INC | Bought | 3,377 | 3,694 | +317 | $ 5,648.94 | |
| METTLER-TOLEDO INTERNATIONAL | Sold | 178 | 174 | −4 | $ -5,110.04 | |
| EIKON THERAPEUTICS INC | Sold | 5,840 | 5,522 | −318 | $ -4,149.90 | |
| DIANTHUS THERAPEUTICS INC | Sold | 848 | 816 | −32 | $ -3,119.36 | |
| CG ONCOLOGY INC | Sold | 2,028 | 1,996 | −32 | $ -2,273.60 | |
| DYNE THERAPEUTICS INC | Bought | 20,969 | 21,069 | +100 | $ 2,221.00 | |
| CVS HEALTH CORP | Bought | 2,698 | 2,717 | +19 | $ 1,965.55 | |
| THERMO FISHER SCIENTIFIC INC | Sold | 1,893 | 1,890 | −3 | $ -1,504.08 | |
| BLACK DIAMOND THERAPEUTICS I | Sold | 15,543 | 15,259 | −284 | $ -525.40 | |
|
CENTESSA PHARMACEUTICALS-ADR CVR
|
New | — | 1,490 | +1,490 | $ 0.00 | |
|
CONTRA APELLIS PHARMAC COMMON STOCK
|
New | — | 499 | +499 | $ 0.00 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up